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INTRODUCTION
To achieve stable donor hematopoietic cell engraftment
with standard doses of allogeneic marrow, conditioning must
prevent rejection of the graft by the host’s immune system
[1] and kill some, but not all, host stem cells to permit the
relatively small numbers of donor stem cells to compete
effectively for hematopoiesis [2]. Although total body irradi-
ation (TBI) is both immunosuppressive and myelotoxic,
comparisons of syngeneic bone marrow transplantation
(BMT) to allogeneic BMT (alloBMT) show that host immu-
nity is the primary barrier to engraftment of allogeneic mar-
row in mice conditioned with low-dose TBI. For example,
stable mixed chimerism following the transplantation of 10 to
20 million mouse marrow cells generally requires ≥700 cGy
TBI conditioning in major histocompatibility complex
(MHC)-incompatible recipients [3], ≥500 cGy TBI in
MHC-compatible allogeneic recipients [4], but only ≥200 cGy
TBI in syngeneic recipients [2,5]. These results have moti-
vated the development of strategies that combine immuno-
suppressive drugs with TBI to suppress host-versus-graft
(HVG) responses and reduce the total TBI dose required for
allogeneic engraftment and mixed chimerism [1,6-8].
Myeloablative doses of TBI are associated with signiﬁ-
cant acute and delayed toxicities. However, efforts to reduce
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ABSTRACT
Cyclophosphamide (Cy) has been studied extensively for its immunosuppressive properties and is frequently com-
bined with total body irradiation (TBI) as conditioning prior to HLA-identical allogeneic blood or marrow trans-
plantation (alloBMT) in humans. Because Cy is most effective at suppressing host-versus-graft reactions when the
drug is given after the transplantation (Mayumi H et al. Transplant Proc. 1986;18:363-369), we investigated whether
posttransplantation Cy could prevent rejection of allogeneic marrow in mice conditioned with low-dose TBI. In a
mouse model, posttransplantation Cy reduced the dose of TBI required from 500 cGy to ≤200 cGy for the engraft-
ment of 10 million major histocompatibility complex (MHC)-identical marrow cells in 100% of recipients. In ani-
mals conditioned with low-dose TBI and posttransplantation Cy, donor chimerism was proportional to the dose of
TBI, was present in multiple hematopoietic lineages, and was associated with the indefinite survival of donor-strain
skin grafts. In contrast, animals conditioned with either TBI alone or posttransplantation Cy alone failed to achieve
engraftment after alloBMT and contained antidonor cytotoxic T-cells. Although <5% donor chimerism could be
induced without TBI by transplanting ≥50 million MHC-identical cells and administering posttransplantation Cy,
the addition of low-dose TBI reduced the dose of donor cells required for alloengraftment and increased long-term
donor chimerism to >50%. These data demonstrate that low-dose TBI and posttransplantation Cy cooperate to
prevent graft rejection following the transplantation of standard doses of MHC-identical marrow cells.
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the dose of TBI in HLA-identical alloBMT have been com-
plicated by an increased risk of graft rejection, which is
likely mediated by radioresistant T-cells specific for non-
MHC, minor histocompatibility antigens (mHAs). By exert-
ing toxicity to recently activated T-cells, cyclophosphamide
(Cy) promotes alloengraftment in both MHC-incompatible
and MHC-compatible donor-recipient pairs of mice. In
MHC-incompatible donor-recipient pairs, posttransplanta-
tion Cy reduces the TBI dose required for induction of
mixed chimerism from 700 cGy to 500 cGy [3]. Chimerism
can even be induced in the xenogeneic rat→mouse combi-
nation using 500 cGy pretransplantation TBI and posttrans-
plantation Cy [9]. When donor and host differ only in the
expression of non-MHC mHAs, posttransplantation Cy can
induce mutual donor-host tolerance, even in the absence of
TBI [10]. However, the method of inducing bidirectional
tolerance with posttransplantation Cy alone may not be fea-
sible in humans for 2 reasons. First, in the mouse model,
≥50 million donor cells (equal to 2.5 × 109 cells/kg) must be
infused prior to administration of Cy for tolerance to ensue
[11]. An equivalent cell dose in humans could be obtained
only by repeated pheresis of the donor and not by a bone
marrow harvest. Second, because Cy at limiting doses does
not destroy host stem cells [12], long-term chimerism is
usually <5% and wanes over time. These observations
prompted us to examine whether a higher level of mixed
chimerism could be achieved following the administration
of fewer marrow cells into MHC-compatible recipients con-
ditioned with the combination of low-dose TBI and post-
transplantation Cy.
MATERIALS AND METHODS
Mice
BALB/cAnNCr (H-2d, CD5.1–, Ly9.1+), DBA/2Cr (H-2d,
CD5.1+), and B6.SJL (H-2b, CD45.1+) mice were all obtained
from the National Cancer Institute (Frederick, MD).
C3H.SW-H-2bSn/J (H-2b, CD45.1–), B10.BR (H-2k), and
B10.D2oSn/J (H-2d, Ly9.1–) mice were obtained from Jackson
Laboratories (Bar Harbor, ME). Mice were maintained in
microisolator cages and were fed autoclaved laboratory chow
and acidiﬁed water, ad libitum. All mice were approximately
6 to 12 weeks old at the time of transplantation.
Cell Preparations
Donor spleens were removed aseptically and pressed
through a nylon mesh to obtain single-cell suspensions. Bone
marrow cell suspensions were prepared by flushing sterile
media through the femoral and tibial marrow canals. Cell sus-
pensions were vigorously pipetted, counted, and washed into
sterile phosphate buffered saline (PBS) prior to injection.
Hematopoietic Cell Transplantation
The method of Cy-induced tolerance [11,13] entails
administration of Cy (Bristol-Myers, Evansville, IN), 50 to
200 mg/kg intraperitoneally (IP), 48 to 72 hours after the
intravenous (IV) administration of MHC-compatible cells
differing in the expression of multiple mHAs. Cy solution
was freshly prepared for each experiment by dissolving the
drug in PBS at a final concentration of 20 mg/mL. Cells
were injected in a ﬁnal volume of 0.5 mL PBS. Some ani-
mals were irradiated by a dual source 137Cs irradiator (Gam-
macell 40; Atomic Energy of Canada, Ottawa, ON, Canada)
at an exposure rate of approximately 82 cGy/min.
Analysis of Leukocyte Chimerism
At designated times after transplantation, blood was
obtained from the lateral tail vein, or animals were killed
and suspensions of spleen and/or bone marrow were pre-
pared. Erythrocytes from the peripheral blood were lysed
using ammonium chloride lysis buffer prior to initiation of
staining. For determination of lineage-specific chimerism,
1 million cells were stained with fluorescein-conjugated
antibody to Ly9.1, CD5.1, or CD45.1 (all from BD
Pharmingen, San Diego, CA) in conjunction with phycoery-
thrin (PE)-conjugated antibodies to CD4 and CD8 (Caltag
Laboratories, Burlingame, CA) or either biotinylated antibody
to B220 or CD11b (both from BD Pharmingen), followed
by PE-conjugated streptavidin (Jackson ImmunoResearch,
West Grove, PA). For staining of granulocytes, cells were
incubated with unconjugated antibody to Gr-1 (gift of Dr. I.
L. Weissman, Stanford University, Palo Alto, CA) followed
by fluorescein isothiocyanate (FITC)-conjugated F(ab)′2
fragments of mouse antibody to rat IgG (Jackson Immuno-
Research). After staining, 5000 to 10,000 live cells were ana-
lyzed by ﬂow cytometry using a ﬂuorescence-activated cell
sorter (FACScan; Becton Dickinson, Franklin Lakes, NJ). In
each experiment, samples of spleen or peripheral blood from
at least 3 host-strain mice that had not undergone trans-
plantation were stained for donor- or host-speciﬁc antigens.
The mean + (3 × SEM) of the percentage of FITC+ donor
cells (or FITC– donor cells in BALB/c recipients of B10.D2
cells) in mice that had not undergone transplantation was
calculated (and was <1% for every experiment), and any
transplant recipient containing a greater percentage of
FITC+ cells than this value was considered to have donor
cell engraftment.
Analysis of Erythroid Chimerism
Hemoglobin patterns were delineated by cellulose
acetate electrophoresis after cystamine modiﬁcation according
to the method described by Whitney [14]. Four microliters
of heparinized whole blood were incubated for 15 minutes
with 7 µL of cystamine solution, a 1:3 dilution of stock con-
taining 112 mg cystamine dihydrochloride, 0.9 mL distilled
water, 0.1 mL of 0.1-mol/L dithiothreitol, and 0.5 mL of
3% ammonium hydroxide solution. Samples were loaded
onto commercially prepared cellulose acetate plates (Titan
III-H Cellulose Acetate; Helena Labs, Beaumont, TX) and
run in an electrophoresis chamber at 300 volts for 20 min-
utes. Following electrophoresis, the samples were stained
with Ponceau S and decolorized 3 times in 5% acetic acid
for 5 minutes each and twice in methanol for 2 minutes
each. Plates were washed in Clear Aid solution (Helena
Labs) for 10 minutes for long-term preservation and densit-
ometric analysis.
Cytotoxic T-Cell Assays 
Four million responder splenocytes and 2 million irradi-
ated (3000 cGy) stimulator spleen cells were added to indi-
vidual wells of a 24-well plate, each well containing 2 mL of
EHAA medium (Biofluids, Rockville, MD), 10% fetal calf
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serum (GIBCO BRL, Gaithersburg, MD), 5 × 10–5M 2-mer-
captoethanol, glutamine, and antibiotics (complete medium;
CM). After 5 days, cells were harvested and plated at various
responder-to-target ratios in 96-well U-bottom plates con-
taining 10,000 3H-labeled target cells (the JAM Test [15]).
Target cells were spleen cells (2 × 106/well) cultured for
48 hours in CM containing 2 µg/mL concanavalin A (Sigma
Chemical Co., St. Louis, MO) and were pulsed for the last
16 hours of culture with 5 µCi 3H-thymidine. After 4 to
5 hours of coculture of responders and targets, cells were
harvested onto glass fiber filters using an automated cell
harvester (Brandel, Gaithersburg, MD), and samples were
counted in a β-scintillation counter.
Skin Grafting
Tail-to-trunk skin grafting was performed as described
[16]. Brieﬂy, recipient mice were anesthetized with a combi-
nation of ketamine and xylazine. A graft bed site over the
left hemithorax was prepared by removing a piece of skin
that was approximately 5 × 5 mm, leaving the panniculus
carnosus and associated blood vessels intact. Tail skin of
similar size was placed onto the graft bed, covered with
Vaseline-impregnated gauze, and the thorax was wrapped
circumferentially with Vet-Wrap (A.J. Buck and Co,
Owings Mills, MD). One week after graft placement, the
bandage was removed and the site was inspected to verify
initial acceptance of the graft. Grafts were inspected at least
3 times per week thereafter, and rejection was considered to
have occurred when no viable graft tissue was present.
RESULTS
Cy Reduces the Dose of TBI Required for the
Induction of Tolerance to mHAs
BALB/c mice (H-2d, Ly9.1+; 5-8 animals per group)
were conditioned with a single dose of TBI, ranging from
100 cGy to 700 cGy, and received transplants of 10 million
MHC-compatible B10.D2 (H-2d, Ly9.1–) marrow cells the
following day. Three days after BMT, animals were left
untreated or received an IP injection of Cy 200 mg/kg. Four
weeks after transplantation, donor lymphoid chimerism in the
peripheral blood was analyzed by ﬂow cytometry (Figure 1).
In animals conditioned with TBI alone, donor T-cell
chimerism was >50% in all animals conditioned with ≥500 cGy
but was <1%, not signiﬁcantly different from nontransplan-
tation control mice, in all animals receiving ≤300 cGy (Fig-
ure 1A). In animals treated with Cy on day 3, donor
chimerism was >5% in all animals conditioned with ≥300 cGy
and in 4 of 5 animals conditioned with 100 cGy (Figure 1),
indicating that Cy lowers the TBI threshold for the induc-
tion of donor chimerism by 200 to 400 cGy. Donor
chimerism was not detected in mice if Cy was given less
than 48 hours or more than 72 hours after marrow transplan-
tation (data not shown), as observed previously in nonirradi-
ated mice [11]. Similar results were obtained in other MHC-
compatible donor-recipient combinations, including DBA/2→
BALB/c, BALB/c→B10.D2, B6.SJL (H-2b)→C3H.SW, and
C3H.SW→B6.SJL (data not shown).
Failure of Allogeneic Cells to Engraft After Low-Dose
TBI Is Associated With the Presence of Antidonor
Cytotoxic T-Lymphocytes
Graft rejection following lethal irradiation and MHC-
identical BMT in humans is associated with the presence of
recipient-derived cytotoxic T-lymphocytes (CTLs) speciﬁc
for donor mHAs [17]. We therefore tested whether the
absence of donor chimerism in mice that had received trans-
plants and were conditioned with low-dose TBI alone is
associated with the presence of antidonor CTLs. BALB/c
mice received 10 million B10.D2 marrow cells after having
been conditioned with 200 cGy TBI alone on day –1, having
been treated with Cy 200 mg/kg IP alone on day 3, or having
Figure 1. Posttransplantation Cy reduces the dose of TBI required for
the engraftment of MHC-compatible cells. BALB/c mice (H-2d,
Ly9.1+) were conditioned with graded doses of irradiation on day –1
and received transplants of 10 million MHC-compatible B10.D2 (H-2d,
Ly9.1–) bone marrow cells on day 0. Seventy-two hours later, animals
received no further treatment (; n = 5 mice per TBI dose) or Cy 200
mg/kg IP (; n = 5-8 mice per TBI dose). Four weeks after transplan-
tation, peripheral blood was stained with fluorescein-conjugated
antibody to Ly9.1 and PE-conjugated antibody to either CD4 or CD8.
A, Mean donor chimerism ±SEM. *Data point represents the mean
chimerism of only the 4 animals with donor engraftment. B, Percent-
age of animals with donor engraftment. Donor engraftment was
deﬁned as >3 × SEM above the mean percentage of T-cells that were
Ly9.1– in BALB/c mice that did not receive transplants (0.38% + [3 ×
0.20%] = 0.98%).
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received the combination of 200 cGy TBI and posttrans-
plantation Cy. Donor chimerism was >50% at 4 months
after transplantation in all animals both conditioned with
low-dose TBI and given posttransplantation Cy (data not
shown). These chimeric animals failed to generate CTLs
against donor-strain B10.D2 cells (Figure 2A). In contrast,
animals that were conditioned with low-dose TBI alone or
treated with posttransplantation Cy alone had <1% donor
chimerism after transplantation and made vigorous CTL
responses in vitro against B10.D2 targets. All animals that
received transplants demonstrated CTL tolerance of host
BALB/c cells (Figure 2B) and reactivity against third-party
BALB.B (H-2b) targets (Figure 2C). Cy-induced CTL
tolerance displayed rapid kinetics of onset. In a separate
experiment, C3H mice (H-2k) were rendered tolerant of
MHC-compatible AKR cells using posttransplantation Cy
and were challenged intraperitoneally with both AKR and
B10.BR (H-2k) cells 1 day after Cy administration. Three
weeks after this challenge, spleen cells from the C3H mice
generated CTLs against B10.BR but not against AKR cells
(data not shown), demonstrating that specific tolerance
induction had occurred as early as 1 day after Cy administra-
tion. Taken together, the results indicate that the mHA-
specific CTL precursors that survive conditioning with
200 cGy TBI are selectively eliminated by the combination
of antigen exposure followed by posttransplantation Cy.
Low-Dose TBI and Posttransplantation Cy Induce
Multilineage Donor Chimerism
To characterize donor chimerism in distinct hemato-
poietic lineages, transplantation was performed between
mHA-incompatible strains of mice that also differed in the
expression of alleles of CD45, the common leukocyte antigen,
and in hemoglobin electrophoretic patterns. C3H.SW (H-2b,
CD45.2+) mice received 200 cGy TBI on day –1, 10 million
MHC-compatible B6.SJL (H-2b, CD45.1+) marrow cells on
day 0, and Cy 200 mg/kg IP on day 3. Substantial donor
chimerism at 6 months after transplantation was detected in
splenic CD4+ and CD8+ T-cells (Figure 3, A and B), thymo-
cytes (Figure 3C), peripheral blood T-cells (Figure 3D),
B220+ B-cells (Figure 3E), CD11b+ monocyte/macrophages
(Figure 3F), and peripheral blood granulocytes (Figure 3G).
Figure 2. Failure of allogeneic marrow to engraft is associated with the presence of antidonor CTLs. BALB/c mice were conditioned with 200 cGy
TBI alone on day –1 (; n = 3), Cy 200 mg/kg IP alone on day 3 (; n = 3), or both (H17009; n = 3). All conditioned mice received 10 million B10.D2
bone marrow cells IV on day 0. Four months after transplantation, spleen cells from the recipients were cultured for 5 days with irradiated BALB/c,
B10.D2, or MHC-incompatible B10.BR stimulators and tested for killing of 3H-labeled host BALB/c (A), donor B10.D2 (B), or third-party B10.BR
targets (C). Each data point represents the mean (±SEM) killing from 3 animals tested individually.
Figure 3. Transplantation of MHC-compatible cells after condition-
ing C3H.SW mice with low-dose TBI and posttransplantation Cy
results in multilineage engraftment. C3H.SW mice (H-2b, CD45.2+)
received 200 cGy TBI on day –1, 10 million B6.SJL marrow cells (H-2b,
CD45.1+) on day 0, and Cy 200 mg/kg IP on day 3. A-G, Six months
after transplantation, splenocytes, thymocytes, or peripheral blood cells
were stained with FITC-conjugated (E and F) or PE-conjugated (A-D
and G) antibody against CD45.1 (donor) and ﬂuorochrome-conjugated
antibodies against lineage-speciﬁc markers: CD4 (T-cell; A, C, and D),
CD8 (T-cell; B, C, and D), B-220 (B-cell, E), CD11b (granulocyte/
macrophage, F), or Gr-1 (granulocyte, G). Numbers in each quadrant
represent the percentage of total cells. H, Erythrocyte chimerism in the
peripheral blood was analyzed by cellulose acetate electrophoresis after
cystamine modification [14]. Five mice were analyzed; typical results
from an individual mouse are shown.
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Hemoglobin electrophoresis demonstrated that red blood
cells were derived almost exclusively from the donor (Fig-
ure 3H, right lane). A detailed kinetic analysis of the evolu-
tion of multilineage engraftment was not performed,
although peripheral blood T-cell chimerism was lower at ear-
lier time points (eg, compare Figure 1A with Figure 3D),
consistent with the paucity of mature T-cells in the marrow
graft and eventual repopulation of the peripheral T-cell pool
with donor-derived thymocytes (Figure 3C). Mixed
chimerism in animals prepared with 200 cGy pretransplanta-
tion TBI and treated with posttransplantation Cy was stable
for more than 1 year. Consistent with the absence of GVHD
in mixed hematopoietic chimeras [18,19], animals that had
undergone transplantations did not lose weight [20] or show
clinical signs of acute or chronic GVHD, such as rufﬂed fur,
hunched posture, diarrhea, or dermatitis for more than 1 year.
Tolerance of Allogeneic Marrow Induced by 
Low-Dose TBI and Posttransplantation Cy Leads 
to Donor-Specific Skin Graft Acceptance
Skin grafting was performed to test for the presence of
functional, in vivo tolerance in animals receiving nonmye-
loablative conditioning. C3H.SW mice were conditioned
with 200 cGy TBI on day –1 and Cy 200 mg/kg IP on day
3, and received either no donor marrow or 107 B6.SJL mar-
row cells on day 0. Six to 8 weeks after transplantation, mice
received on the trunk grafts of tail skin from B6.SJL,
C3H.SW, or third-party BALB/c x DBA/2 F1 (H-2
d)
donors. C3H.SW recipients of TBI, B6.SJL marrow cells,
and posttransplantation Cy accepted skin grafts from either
C3H.SW or B6.SJL donors but promptly rejected grafts
from third-party CD2 F1 mice (Figure 4A). In contrast,
C3H.SW mice that were conditioned but did not receive
B6.SJL marrow accepted only C3H.SW skin grafts and
rejected both B6.SJL and CD2 F1 skin (Figure 4B). Thus,
the level of donor chimerism that is induced by transplanta-
tion of MHC-identical marrow in mice that received low-dose
TBI and posttransplantation Cy is sufﬁcient for acceptance
of parenchymal tissue grafts from the same donor.
Long-term Donor Chimerism After
Pretransplantation TBI and Posttransplantation Cy 
Is Proportional to the Dose of Irradiation
We next examined the effect of varying the dose of pre-
transplantation TBI or donor marrow cells on donor
chimerism within the spleens of C3H.SW mice at 8 months
after induction of tolerance to B6.SJL bone marrow. Donor
hematopoietic chimerism was primarily a function of recipi-
ent irradiation, whereas increasing the dose of transplanted
marrow from 10 million to 20 million cells had little, if any,
effect (Figure 5). The percentage of long-term donor
chimerism was linearly related to the irradiation dose up to
200 cGy TBI, at which point a plateau was reached. Donor
chimerism within the spleen was also observed in 4 of 5 ani-
mals receiving 50 cGy TBI and 20 million donor cells, and
in all animals receiving ≥100 cGy TBI and ≥10 million
donor cells. These results indicate that durable engraftment
of mHA-disparate cells can be achieved with as little as
50 cGy TBI if it is combined with posttransplantation Cy.
Pretransplantation TBI Reduces the Dose of Cells
Required for Tolerance Induction
Previous studies using MHC-compatible donor-recipient
pairs of mice have shown that posttransplantation Cy alone
induces tolerance and stable microchimerism (<5%) without
the need for pretransplantation TBI, but only if the graft con-
tains ≥50 million cells [11]. When C3H.SW mice (n = 5)
received 20 million marrow cells from MHC-compatible
B6.SJL donors on day 0 and Cy 200 mg/kg IP on day 3,
peripheral blood donor chimerism at 6 months after transplan-
tation was <0.05% in each of the mice, not signiﬁcantly differ-
ent than that for nontransplantation C3H.SW control mice.
However, donor chimerism at 6 months after transplantation
Figure 4. Engraftment of allogeneic marrow cells after low-dose TBI
and posttransplantation Cy is associated with donor strain–speciﬁc skin
graft acceptance. C3H.SW mice (n = 4 per group) were conditioned
with 200 cGy TBI on day –1 and treated with Cy 200 mg/kg IP on day
3. On day 0, conditioned mice received 10 million B6.SJL marrow cells
(A) or nothing (B). Six to 8 weeks later, mice received grafts of either
host C3H.SW (), donor B6.SJL (), or third-party allogeneic
BALB/c × DBA/2 (CD2) F1 skin (). Rejection was deemed to have
occurred when no visible grafted tissue remained.
Figure 5. Long-term donor chimerism in mice that underwent trans-
plantation is proportional to the dose of total body irradiation.
C3H.SW mice (n = 5 per group) received graded doses of TBI on day
–1, 10 million () or 20 million () B6.SJL marrow cells on day 0, and
Cy 200 mg/kg IP on day 3. Eight months after transplantation, spleno-
cytes were stained with FITC-conjugated antibody against CD45.1
(donor) and analyzed for donor chimerism by ﬂow cytometry. Data are
plotted as median donor chimerism/group ±SEM.
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was 69.9% ±8.7% (mean ±SEM) in 6 C3H.SW recipients of
200 cGy TBI on day –1, 10 million B6.SJL marrow cells on
day 0, and Cy 200 mg/kg IP on day 3. These results demon-
strate that the cell dose threshold for the induction of stable
macrochimerism by posttransplantation Cy is effectively low-
ered by the addition of pretransplantation low-dose TBI.
DISCUSSION
A major goal of clinical transplantation is to induce allo-
geneic hematopoietic chimerism with a minimum of acute
and long-term procedural toxicities. Donor cell engraftment
can be reliably induced by transplantation of allogeneic
marrow following conditioning with myeloablative doses of
TBI. However, high-dose TBI is associated with signiﬁcant
acute and delayed toxicities, including infection, mucositis,
sterility [21], growth and developmental defects in children
[22], and secondary malignancies [23]. Moreover, increasing
the dose of TBI prior to alloBMT augments the risk of allo-
geneic GVHD [24,25]. Thus, efforts to reduce the dose of
TBI as conditioning for alloBMT without increasing the
risk of graft rejection are warranted.
In this report, we show that posttransplantation Cy
reduces, by 200 to 400 cGy, the dose of TBI that is required
for the engraftment of 10 million MHC-identical bone mar-
row cells differing in the expression of multiple mHAs.
Interestingly, studies have also demonstrated that tolerance
of MHC-mismatched cardiac allografts can be induced by
donor spleen cell transfusion followed in 2 to 3 days by
administration of the soluble fusion protein CTLA-4Ig
[26,27], which blocks T-cell costimulatory interactions [28].
As in our approach, animals treated with costimulatory
blockade in this sequence remained immunocompetent but
exhibited donor-specific unresponsiveness. Recently, new
insights into the mechanisms of peripheral tolerance induc-
tion and the importance of deletion of activated T-cells
through activation-induced cell death have been described
[29,30]. These studies provide strong evidence that alloanti-
gen recognition and subsequent apoptosis of mature allore-
active T-cells are essential for the induction of stable
peripheral tolerance. Thus, administration of Cy and selec-
tive elimination of donor-reactive host T-cells after initial
antigenic challenge [31] follow the basic requirements for
the induction of peripheral tolerance: (1) antigenic chal-
lenge and proliferation of T-cells, and (2) selective elimina-
tion of proliferating T-cells [32,33]. Most likely, the speciﬁc
deletion of alloactivated cells in the Cy-induced tolerance
approach occurs because of the high sensitivity of proliferat-
ing cells to Cy [34]. In adult mice, the induction of tolerance
in mature peripheral T-cells is a prerequisite for the estab-
lishment of central alloantigen tolerance, which requires
intrathymic mixed chimerism and is mediated by the clonal
deletion of alloreactive thymocytes [35].
Low-dose TBI regimens for MHC-identical BMT have
been developed in dogs and translated to the clinic for the
treatment of patients with hematologic cancers. In dogs,
engraftment of DLA-identical marrow was achieved in 4 of
5 recipients conditioned with 200 cGy TBI on day –1 and
treated with cyclosporin A and mycophenolate mofetil after
the transplantation [1]. When this regimen was applied to
hematologic-malignancy patients receiving HLA-identical
peripheral blood stem cell grafts, a 20% incidence of nonfa-
tal graft rejection was observed [6]. Rejection of HLA-identical–
sibling grafts was completely abrogated by the addition of IV
ﬂudarabine on days –4 through –2; however, HLA-identical
stem cell grafts from unrelated donors were rejected by 12%
of patients receiving the same conditioning [36]. The addition
of posttransplantation Cy to regimens that contain low-dose
TBI, with or without ﬂudarabine, may confer 2 advantages.
First, we have found that posttransplantation Cy increases the
degree of host immunosuppression in mice conditioned with
ﬂudarabine and TBI, and the combination of these 3 agents is
sufficient for the stable engraftment of even fully MHC-
incompatible marrow [37]. Thus, posttransplantation Cy, when
combined with pretransplantation ﬂudarabine and 200 cGy
TBI, may reduce the risk of rejection of HLA-identical
unrelated-donor grafts. Second, posttransplantation Cy ame-
liorates GVHD [38,39], a major complication of nonmyeloab-
lative allogeneic stem cell transplantation following low-dose
TBI regimens in humans [6]. The effect of posttransplantation
Cy on GVH reactions in MHC-identical donor-recipient
pairs of mice has been characterized extensively by Eto and
colleagues [40]. These investigators found that Cy kills
mature, host-reactive T-cells and promotes the establishment
of intrathymic mixed chimerism and clonal deletion of devel-
oping host-reactive thymocytes. Although engraftment, rather
than GVHD, was the focus of the current study, the presence
of stable mixed chimerism and the absence of CTLs against
host cells (Figure 2) are both consistent with the absence of
signiﬁcant GVH reactions in our model.
Based on studies in animals, low-dose posttransplanta-
tion Cy was used to prevent GVHD after lethal conditioning
and BMT of HLA-identical–sibling donor cells. However,
posttransplantation methotrexate was superior to posttrans-
plantation Cy in the prevention of GVHD following DLA-
mismatched BMT in dogs [41], and Cy was found to be
inferior to cyclosporin A as a posttransplantation prophylaxis
for GVHD in HLA-identical alloBMT [42]. Because of
these results, the strategy of administering Cy after myeloab-
lative BMT was abandoned. However, these ﬁndings do not
rule out a role for posttransplantation Cy in HLA-identical
nonmyeloablative alloBMT. The dose and timing of Cy
treatment in these studies may not have been optimal for the
induction of tolerance, which in mice requires the adminis-
tration of a single high dose of Cy on day 2 or 3 after trans-
plantation [11]. Concerns about the effect of a high dose of
Cy on donor stem cells and the recovery of hematopoiesis
are allayed to some extent by the ﬁnding of high aldehyde
dehydrogenase levels and resistance to Cy among hemato-
poietic stem cells [43]. Ultimately, however, the efﬁcacy of
posttransplantation Cy in promoting engraftment and
inhibiting GVHD following HLA-identical nonmyeloabla-
tive alloBMT must be assessed in clinical trials.
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